

Amendments to the Claims

1. (Original) A method for treating inflammatory diseases of the external segment or the anterior segment of the eyes, which comprises administering an aqueous eye drop comprising 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof once a day, and maintaining a therapeutically effective concentration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid in the anterior aqueous humor for at least 24 hours after the intraocular administration.

2. (Original) The method according to claim 1, wherein the aqueous eye drop comprising 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof comprises an organic amine or a salt thereof, and the content of the aforementioned organic amine or salt thereof is an amount to allow the octanol-water partition coefficient of 2-amino-3-(4-bromobenzoyl)phenylacetic acid to be 0.7 to 4.

3. (Currently amended) The method according to claim 1 ~~or claim 2~~, wherein the concentration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof in the aqueous eye drop is 0.01 to 0.5w/v%.

4. (Original) The method according to claim 2, wherein the organic amine is at least one member selected from the group consisting of an amino acid, an alkanolamine, a diamine, a piperazine, and an aminoalkylsulfonic acid.

5. (Currently amended) The method according to claim 2 ~~or claim 4~~, wherein the organic amine is an amino acid and its concentration is 0.35 to 5w/v%.

6. (Currently amended) The method according to claim 2 ~~or claim 4~~, wherein the organic amine is an alkanolamine and its concentration is 0.15 to 0.95w/v%.

7. (Original) The method according to claim 6, wherein the alkanolamine is trometamol.

8. (Currently amended) The method according to claim 2 ~~or claim 4~~, wherein the organic amine is a diamine and its concentration is 0.05 to 5w/v%.

9. (Currently amended) The method according to claim 2 ~~or claim 4~~, wherein the organic amine is a piperazine and it is contained at a concentration of 0.05 to 5w/v% in the aqueous eye drop.

10. (Currently amended) The method according to claim 2 ~~or claim 4~~, wherein the organic amine is an aminoalkylsulfonic acid and its concentration is 0.05 to 5w/v%.

11. (Currently amended) The method according to claim 10, wherein the aminoalkylsulfonic acid is aminoethylsulfonic acid.

12. (Original) A method for promoting intraocular penetration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, which comprises administering an aqueous eye drop comprising 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof comprises an organic amine or a salt thereof, wherein the content of said organic amine or salt thereof is an amount to allow the octanol-water partition coefficient of 2-amino-3-(4-bromobenzoyl)phenylacetic acid to be 0.7 to 4.

13. (Original) An aqueous eye drop for once a day administration for treating inflammatory diseases of the external segment or the anterior segment of the eyes, characterized in that a therapeutically effective concentration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof is maintained in the anterior aqueous humor for at least 24 hours by once a day administration.

14. (Original) The aqueous eye drop according to claim 13, wherein the concentration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof in the aqueous eye drop is 0.01 to 0.5w/v%.

15. (Currently amended) The aqueous eye drop according to claim 13 ~~or claim 14~~, wherein the aqueous eye drop comprising 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof comprises an organic amine or a salt thereof, and the content of said organic amine or salt thereof is an amount to allow the octanol-water partition coefficient of 2-amino-3-(4-bromobenzoyl)phenylacetic acid contained in the aqueous eye drop to be 0.7 to 4.

16. (Original) The aqueous eye drop according to claim 15, wherein the organic amine is at least one member selected from the group consisting of an amino acid, an alkanolamine, a diamine, a piperazine, and an aminoalkylsulfonic acid.

17. (Currently amended) The aqueous eye drop according to claim 15 ~~or claim 16~~, wherein the organic amine is an amino acid and its concentration is 0.35 to 5w/v%.

18. (Currently amended) The aqueous eye drop according to claim 15 ~~or claim 16~~, wherein the organic amine is an alkanolamine and its concentration is 0.15 to 0.95w/v%.

19. (Original) The aqueous eye drop according to claim 18, wherein the alkanolamine is trometamol.

20. (Currently amended) The aqueous eye drop according to claim 15 ~~or claim 16~~, wherein the organic amine is a diamine and its concentration is 0.05 to 5w/v%.

21. (Currently amended) The aqueous eye drop according to claim 15 or ~~claim 16~~, wherein the organic amine is a piperazine and it is contained at a concentration of 0.05 to 5w/v% in the aqueous eye drop.

22. (Currently amended) The aqueous eye drop according to claim 15 or ~~claim 16~~, wherein the organic amine is an aminoalkylsulfonic acid and its concentration is 0.05 to 5w/v%.

23. (Original) The aqueous eye drop according to claim 22, wherein the aminoalkylsulfonic acid is aminoethylsulfonic acid.

24. (Original) An aqueous eye drop for once a day for treating inflammatory diseases of the external segment or the anterior segment of the eyes, characterized in that a therapeutically effective concentration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid is maintained in the anterior aqueous humor for at least 24 hours by once a day administration of 0.01 to 0.5w/v% 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof and 0.05 to 5w/v% aminoethylsulfonic acid.

25. (Currently amended) ~~Use of an organic amine or its salt~~ A method for producing an aqueous eye drop which is to be administered once a day, characterized in that the aqueous eye drop comprising 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof is administered once a day, and a therapeutically effective concentration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid is maintained in the anterior aqueous humor for at least 24 hours by once a day administration to treat inflammatory diseases of the external segment or the anterior segment of the eyes.

26. (Currently amended) The ~~use~~ method according to claim 25, wherein the concentration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof in the aqueous eye drop is 0.01 to 0.5w/v%.

27. (Currently amended) The use method according to claim 25 ~~or claim 26~~, wherein the amount of the organic amine or its salt used is an amount to allow the octanol-water partition coefficient of 2-amino-3-(4-bromobenzoyl)phenylacetic acid to be 0.7 to 4.

28. (Currently amended) The use method according to claim 27, wherein the organic amine is at least one member selected from the group consisting of an amino acid, an alkanolamine, a diamine, a piperazine, and an aminoalkylsulfonic acid.

29. (Currently amended) The use method according to claim 27 ~~or claim 28~~, wherein the organic amine is an amino acid, and its concentration is 0.35 to 5w/v%.

30. (Currently amended) The use method according to claim 27 ~~or claim 28~~, wherein the organic amine is an alkanolamine, and its concentration is 0.15 to 0.95w/v%.

31. (Currently amended) The use method according to claim 30, wherein the alkanolamine is trometamol.

32. (Currently amended) The use method according to claim 27 ~~or claim 28~~, wherein the organic amine is a diamine, and its concentration is 0.05 to 5w/v%.

33. (Currently amended) The use method according to claim 27 ~~or claim 28~~, wherein the organic amine is a piperazine, and it is contained at a concentration of 0.05 to 5w/v% in the aqueous eye drop.

34. (Currently amended) The use method according to claim 27 ~~or claim 28~~, wherein the organic amine is an aminoalkylsulfonic acid, and its concentration is 0.05 to 5w/v%.

35. (Currently amended) The ~~use~~ method according to claim 34, wherein the aminoalkylsulfonic acid is aminoethylsulfonic acid.